BIOLASE

BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Lake Forest, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

BIOLASE reports strong Q1 performance, eyes profitability through market growth

BIOLASE's Q1 2024 earnings reflect a robust performance with growth in sales and improved financial metrics. The company's strategic focus on accelerating dental laser adoption and operational enhancements position it well for future success. While challenges exist in achieving profitability, BIOLASE's opportunities in the dental market and growth initiatives offer a positive outlook.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1984 and is headquartered in Lake Forest, CA.

LAKE FOREST, CA / ACCESSWIRE / October 1, 2024 / BIOLASE, Inc. (NASDAQ:BIOL) (the "Company"), a global leader in dental lasers, today announced that the Company and its direct domestic subsidiaries have voluntarily initiated Chapter 11 proceedings (the "Bankruptcy Petitions") in the United States Bankruptcy Court for the District of Delaware (the "Court"). BIOLASE will seek Court approval to continue operating during the proceedings and remains focused on providing its customers with its award-winning dental lasers and customer service.

BIOLASE Voluntarily Initiates Chapter 11 Proceedings

LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024. "We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE.

BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

LAKE FOREST, CA / ACCESSWIRE / June 18, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today announced that the Company received a notice from Nasdaq that it has determined to delist the shares of the Company's common stock from The Nasdaq Stock Market. The delisting is a result of failure to satisfy the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) and failure to comply with Nasdaq's $2,500,000 minimum stockholders' equity requirement for continued listing or any of the alternative requirements in Listing Rule 5550(b).

BIOLASE Announces Delisting from Nasdaq

BIOLASE, Inc. (NASDAQ:BIOL ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Michael Polyviou - Investor Relations John Beaver - President and Chief Executive Officer Jennifer Bright - Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company Ed Woo - Ascendiant Capital Operator Good day, and welcome to the BIOLASE First Quarter 2024 Results Conference Call. All participants will be in a listen-only mode.

BIOLASE, Inc. (BIOL) Q1 2024 Earnings Call Transcript

Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and Success LAKE FOREST, CA / ACCESSWIRE / May 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024. First Quarter Financial Highlights Generated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialists Third strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptions Gross margin was relatively flat compared to the year-ago quarter; however, it improved by 1% year over year as the Company continues to benefit from 100% of its trunk fiber requirements now being supplied in-house and improved by 7% compared to the prior quarter from inventory adjustments and reserve charges recorded in the fourth quarter ended December 31, 2023 Significantly lowered Adjusted EBITDA loss by 21% versus the same quarter last year, as cost reduction initiatives achieved desired outcomes Full Year 2024 Financial Guidance Reiterates 2024 full-year financial guidance, in which it expects: 2024 full-year net revenue to increase between 6% and 8% year over year to between $52 million and $53 million.

Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability

LAKE FOREST, CA / ACCESSWIRE / May 6, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release first quarter 2024 financial and operating results on Monday, May 13, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m.

BIOLASE to Report First Quarter 2024 Results on May 13, 2024

BIOLASE, Inc. (BIOL) Q4 2023 Earnings Call Transcript

LAKE FOREST, CA / ACCESSWIRE / March 21, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, who previously announced its preliminary financial results for the fourth quarter and full year ended December 31, 2023, today reported its financial results for the quarter and full year. 2023 Full-Year Highlights Achieved revenue growth despite industry headwinds and a challenging interest rate environment throughout 2023.

Biolase Reports Full-Year 2023 Results; Expects Continued Revenue Growth In 2024

LAKE FOREST, CA / ACCESSWIRE / March 14, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release fourth quarter and full year 2023 financial and operating results on Thursday, March 21, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m.

BIOLASE to Report Fourth Quarter and Full Year 2023 Results on March 21, 2024

Waterlase iPlus Premier Edition™ is being unveiled at the Chicago Midwinter Meeting 2024 LAKE FOREST, CA / ACCESSWIRE / February 22, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, has launched its state-of-the-art all-tissue laser system, Waterlase iPlus Premier Edition™, and will be debuting it at the Chicago Midwinter Meeting 2024 from February 22nd to 24th at booth 4608. The Waterlase iPlus Premier Edition™ is an extraordinary update to the industry-leading Waterlase iPlus and represents the pinnacle of innovation in dental care.

Biolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in Dentistry

LAKE FOREST, CA / ACCESSWIRE / February 20, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, remains committed to expanding its educational offerings through its web portal, enabling dental clinicians to elevate their standard of dental care and improve patient outcomes through laser technology. "Let's Talk Dental," a free webinar series focused on a variety of topics covering all dental disciplines, kicked off the year with a webinar on January 18, 2024, hosted by Dr. Paul Chang, a periodontist and prosthodontist with a private practice in McKinney, Texas.

Biolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental'

LAKE FOREST, CA / ACCESSWIRE / February 15, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced the closing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock. Each unit was sold at an effective public offering price of $0.44.

BIOLASE, Inc. Announces Closing of $7.0 Million Public Offering

LAKE FOREST, CA / ACCESSWIRE / February 14, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that it received notice from the Staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that the Staff has determined to grant the Company an extension of time to regain compliance with Listing Rule 5550(b) (the "Rule"). The Rule requires a minimum of $2,500,000 stockholders' equity, $35,000,000 market value of listed securities, or $500,000 net income from continuing operations.

BIOLASE, Inc. Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement

LAKE FOREST, CA / ACCESSWIRE / February 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced the pricing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock. Each unit is being sold at an effective public offering price of $0.44.

BIOLASE, Inc. Announces Pricing of $7.0 Million Public Offering

CNS Pharmaceuticals

Gilead Sciences

Revelation Biosciences

Zai Lab Ltd.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Are Preparing To Pump In February

Expects Continued Revenue Growth in 2024 and Takes Steps to Further Improve Operating Efficiency as the Company Pursues Profitability Goals LAKE FOREST, Calif. , Jan. 29, 2024 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced preliminary unaudited revenue results for 2023 based on currently available information and expects to report year-over-year growth as it continues to generate interest among dental practitioners for its industry leading lasers.

BIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023 AND PROVIDES OUTLOOK FOR FULL YEAR 2024

Robust Educational Courses Commence with an Advanced Mastery Course on February 2–3, 2024 LAKE FOREST, Calif. , Jan. 8, 2024 /PRNewswire/ -- BIOLASE, Inc.  (NASDAQ: BIOL), the global leader in dental lasers, has experienced growing demand for its robust educational offering and as a result has increased the number of dental laser courses planned for the first quarter of 2024.

BIOLASE ENHANCES EDUCATION OFFERINGS IN 2024 DUE TO INCREASING DEMAND OF DENTAL LASER COURSES THROUGHOUT 2023

LAKE FOREST, Calif. , Jan. 3, 2024 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that the Company has been awarded a Top Workplaces 2023  honor by the Inland News Group.

BIOLASE RECEIVES SECOND TOP WORKPLACES 2023 AWARD

LAKE FOREST, Calif. , Dec. 14, 2023 /PRNewswire/ --  BIOLASE, Inc.  (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been awarded a Top Workplaces 2023 honor by Orange County Register Top Workplaces.

BIOLASE RECEIVES TOP WORKPLACES 2023 AWARD

Receives Overwhelmingly Positive Dentist Feedback and Unanimous Approval During Independently led Trial Results Demonstrate 100% Performance Satisfaction and Recommendation of Wider Adoption among Dental Practices LAKE FOREST, Calif. , Dec. 12, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced the successful completion of a trial program featuring the Waterlase iPlus All Tissue laser conducted by six leading U.S. dentists.

BIOLASE Successfully Concludes Waterlase iPlus All Tissue Laser Trial

LAKE FOREST, Calif. , Dec. 6, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.4 million of its common stock and pre-funded warrants in a registered direct offering and warrants to purchase common stock in a concurrent private placement, priced at-the-market under Nasdaq rules.

BIOLASE, Inc. Announces Pricing of $1.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LAKE FOREST, Calif. , Nov. 9, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the third quarter ended September 30, 2023.

BIOLASE REPORTS THIRD QUARTER FINANCIAL RESULTS; COMPANY BENEFITTING FROM STRATEGIC ACTIONS TAKEN TO STREAMLINE OPERATIONS AND GAIN GREATER OPERATIONAL EFFICIENCIES

Validates   BIOLASE REPAIR® Perio Protocol is a Superior Alternative as it pertains to patient reported outcomes. LAKE FOREST, Calif.

Landmark Study Performed by the Independent McGuire Institute Confirms Positive 12 Month Clinical Outcomes for BIOLASE REPAIR® Perio Protocol

LAKE FOREST, Calif. , Nov. 7, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release third quarter 2023 financial and operating results on Thursday, November 9, 2023, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m.

BIOLASE TO REPORT THIRD QUARTER 2023 RESULTS ON NOVEMBER 9, 2023

LAKE FOREST, Calif. , Sept. 18, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL) ("BIOLASE" or the "Company"), a global leader in dental lasers, today announced the closing of its previously announced underwritten public offering of 75,000 units (the "Units"), with each Unit consisting of one share of BIOLASE's Series J Convertible Redeemable Preferred Stock, par value $0.001 per share, with a liquidation preference of $100.00 per share (the "Series J Convertible Preferred Stock"), and one warrant (the "Warrants") to purchase one-half of one (0.50) share of Series J Convertible Preferred Stock.

News for BIOLASE Stock (BIOL)